Loading...

Brilliant Violet 785™ anti-mouse CD45 Antibody

Pricing & Availability
Clone
30-F11 (See other available formats)
Regulatory Status
RUO
Other Names
T200, Ly-5, LCA
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
30-F11_BV785_CD45_Antibody_FC_121014
C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 785™ (filled histogram) or rat IgG2b, κ Brilliant Violet 785™ isotype control (open histogram).
  • 30-F11_BV785_CD45_Antibody_FC_121014
    C57BL/6 mouse splenocytes were stained with CD45 (clone 30-F11) Brilliant Violet 785™ (filled histogram) or rat IgG2b, κ Brilliant Violet 785™ isotype control (open histogram).
See Brilliant Violet 785™ spectral data
Cat # Size Price Quantity Check Availability Save
103149 50 µg 273 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45 is a 180-240 kD glycoprotein also known as the leukocyte common antigen (LCA), T200, or Ly-5. It is a member of the protein tyrosine phosphatase (PTP) family, expressed on all hematopoietic cells except mature erythrocytes and platelets. There are different isoforms of CD45 that arise from variable splicing of exons 4, 5, and 6, which encode A, B, and C determinants, respectively. CD45 plays a key role in TCR and BCR signal transduction. These isoforms are very specific to the activation and maturation state of the cell as well as cell type. The primary ligands for CD45 are galectin-1, CD2, CD3, CD4, TCR, CD22, and Thy-1.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 785™ under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 785™ excites at 405 nm and emits at 785 nm. The bandpass filter 780/60 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 785™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone 30-F11 reacts with all isoforms and both CD45.1 and CD45.2 alloantigens of CD45.

Additional reported applications (for relevant formats) include: immunoprecipitation3, complement-dependent cytotoxicity1,5, immunohistochemistry (acetone-fixed frozen sections, zinc-fixed paraffin-embedded sections and formalin-fixed paraffin-embedded sections)4,6, Western blotting7, and spatial biology (IBEX)10,11. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 103163 and 103164).

Application References

(PubMed link indicates BioLegend citation)
  1. Podd BS, et al. 2006. J. Immunol. 176:6532. (FC, CMCD) PubMed
  2. Haynes NM, et al. 2007. J. Immunol. 179:5099. (FC)
  3. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IP)
  4. Simon DI, et al. 2000. J. Clin. Invest. 105:293. (IHC)
  5. Seaman WE. 1983. J. Immunol. 130:1713. (CMCD)
  6. Cornet A, et al. 2001. P. Natl. Acad. Sci. USA 98:13306. (IHC)
  7. Tsuboi S and Fukuda M. 1998. J. Biol. Chem. 273:30680. (WB) PubMed
  8. Liu F, et al. 2012. Blood. 119:3295. PubMed
  9. Pelletier AN, et al. 2012. J. Immunol. 188:5561. PubMed
  10. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  11. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Michela Miani et al. 2018. Cell metabolism. 28(4):557-572 . PubMed
  2. Tavazoie MF, et al. 2018. Cell. 172:825. PubMed
  3. Lang JF et al. 2019. Nat Commun. 10(1):3415 . PubMed
  4. Haertel E, et al. 2018. Eur J Immunol. 48:1001. PubMed
  5. Privratsky JR, et al. 2018. Am J Physiol Renal Physiol. 315:F682. PubMed
  6. Lu X, et al. 2019. Circ Res. 125:1055. PubMed
  7. Angiari S, et al. 2020. Cell Metab. 31:391. PubMed
  8. Leylek R, et al. 2019. Cell Rep. 29:3736. PubMed
  9. Maniati E, et al. 2020. Cell Rep. 30:525. PubMed
  10. Davidson S, et al. 2020. Cell Reports. 31(7):107628. PubMed
  11. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  12. Pereira JA, et al. 2020. Hum Mol Genet. 29:1253. PubMed
  13. Muri J, et al. 2020. Cell Reports. 29(9):2731-2744.e4.. PubMed
  14. Lee H, et al. 2020. Cell Metabolism. 31(4):822-836. PubMed
  15. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  16. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
  17. Kienzl M, et al. 2020. Oncoimmunology. 9:1776059. PubMed
  18. Burns JC, et al. 2020. eLife. 9:00. PubMed
  19. Rodriguez AB, et al. 2021. Cell Reports. 36(3):109422. PubMed
  20. Freed-Pastor WA, et al. 2021. Cancer Cell. 39:1342. PubMed
  21. Tan J, et al. 2021. iScience. 24(8):102835. PubMed
  22. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  23. Johnson LA, et al. 2021. Life Sci Alliance. :4. PubMed
  24. Santopaolo M, et al. 2021. Front Immunol. 609406:12. PubMed
  25. Ostendorf BN, et al. 2020. Nat Med. 26:1048. PubMed
  26. Kuang Z, et al. 2020. Antib Ther. 3:227. PubMed
  27. Filtjens J, et al. 2021. Nat Commun. 12:2936. PubMed
  28. Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  29. Krisna SS, et al. 2021. STAR Protoc. 2:100627. PubMed
  30. Ford MJ, et al. 2021. Cell Rep. 36:109677. PubMed
  31. Gómez-Díaz C, et al. 2021. iScience. 24:103241. PubMed
  32. Rogic A, et al. 2021. Nat Commun. 12:6889. PubMed
  33. Chen F, et al. 2022. Cell Rep. 38:110215. PubMed
  34. Bajaña S, et al. 2022. iScience. 25:103732. PubMed
  35. Lee HN, et al. 2022. JCI Insight. 7:. PubMed
  36. , et al. 2021. Eur J Immunol. 51:2708. PubMed
  37. Myers JA, et al. 2022. JCI Insight. :. PubMed
  38. Burns JC, et al. 2021. Bio Protoc. 11:e4091. PubMed
  39. Fearon AE, et al. 2021. iScience. 24:103143. PubMed
  40. Qadir AS, et al. 2021. iScience. 24:103348. PubMed
  41. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  42. Chen B, et al. 2021. Cell. 184:6262. PubMed
  43. Deets KA, et al. 2021. Elife. 10:. PubMed
  44. Hackstein CP, et al. 2022. Nat Commun. 13:7472. PubMed
  45. Pohlmeier L, et al. 2021. Allergy. 76:2030. PubMed
  46. Kfoury Y, et al. 2021. Cancer Cell. 39:1464. PubMed
  47. Mills EL, et al. 2022. Cell Metab. 34:140. PubMed
  48. Wu J, et al. 2023. Bioact Mater. 20:259. PubMed
  49. Liu H, et al. 2022. Cell Rep Med. 3:100660. PubMed
  50. Ostendorf BN, et al. 2022. Nature. 611:346. PubMed
  51. Hill AA, et al. 2023. JCI Insight. 8: . PubMed
  52. Giannou AD, et al. 2023. Immunity. 56:125. PubMed
  53. Lazure F, et al. 2023. Nat Commun. 14:535. PubMed
  54. Friedman D, et al. 2022. J Immunol. 208:1845. PubMed
  55. Wight AE, et al. 2022. Proc Natl Acad Sci U S A. 119:e2200757119. PubMed
  56. Jia L, et al. 2022. Gut Microbes. 14:2117503. PubMed
  57. Harapas CR, et al. 2022. Sci Immunol. 7:eabi4611. PubMed
  58. Jeon Y, et al. 2022. Cancers (Basel). 14:. PubMed
  59. Latour YL, et al. 2023. Gut Microbes. 15:2192623. PubMed
  60. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
  61. Prasad S, et al. 2023. iScience. 26:106628. PubMed
RRID
AB_2564590 (BioLegend Cat. No. 103149)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

All hematopoietic cells except mature erythrocytes and platelets

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4, TCR, CD22, Thy-1
Cell Type
B cells, Dendritic cells, Mesenchymal Stem Cells, Tregs
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Innate Immunity, Neuroscience, Neuroscience Cell Markers, Stem Cells
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID
UniProt
View information about CD45 on UniProt.org
Go To Top Version: 1    Revision Date: 12.12.2014

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account